ArticleAnnals of medicine and surgery (2012)2026
Targeting neuronal pentraxin 1 microRNA-492 exerts pro-tumorigenic effects in colorectal cancer through stimulation of proliferation, migration, and invasion.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is one of the most common cancer types affecting both men and women. MicroRNA-492 (miR-492) plays an important role in the development of various malignant tumors; however, its specific role and related mechanisms in CRC remain unclear. Therefore, we aimed to explore the relationship between miR-492 and the prognosis of patients with CRC, as well as the specific mechanisms involved in CRC development. Methods: The Gene Expression Omnibus and The Cancer Genome Atlas datasets were downloaded to analyze the relationship between the miR-492 expression level and the overall survival of patients with CRC. Forty-four pairs of primary CRC tissues and paired normal tissues were collected. The relationship between the miR-492 expression level and clinicopathological parameters of patients with CRC was analyzed using statistical methods. MiRNA quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect miR-492 expression levels in CRC tissues and cell lines. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and colony-formation assays were performed to assess cell growth and proliferation, respectively. Transwell assays were performed to analyze the migration and invasion potential of CRC cells. The interaction between miR-492 and 3' untranslated regions (3'-UTRs) of neuronal pentraxin 1 (NPTX1) was evaluated using a luciferase reporter assay. The expression of NPTX1 in CRC tissues and cells was detected by qRT-PCR. Results: Low expression of miRNA-492 in CRC tissues is closely associated with patients' survival prognosis. miR-492 can recognize the 3'-UTR of NPTX1 mRNA and directly target and regulate NPTX1 expression, thereby promoting the growth, migration, and invasion of CRC cells. Conclusions: The ability of miR-492 to mediate the biological behavior of CRC by targeting NPTX1 is associated with poor prognosis and suggests that miR-492 is a potential therapeutic candidate for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.